Callitas Health (Callitas Health) Short Interest

View and export this data going back to 2008. Start your Free Trial

What is Callitas Health Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Callitas Health's Short Interest

For the Biotechnology subindustry, Callitas Health's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Callitas Health's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Callitas Health's Short Interest distribution charts can be found below:

* The bar in red indicates where Callitas Health's Short Interest falls into.

Callitas Health (Callitas Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Callitas Health Inc (OTCPK:MPHMF) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

734 - 1055 Dunsmuir Street, Vancouver, BC, CAN, V7X 1B1

Website

http://www.callitas.com

Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.